Myoclonus.
The diagnosis and treatment of myoclonus pose a particular challenge to the neurologist. Few well-controlled double-blind studies of antimyoclonic agents have been performed, and clinical rating of the effectiveness of treatment has been primarily descriptive. As a result, therapy is often empiric. This article reviews the author's approach to treating patients with myoclonus. Three principles guide treatment. First, the cause and physiology of the myoclonic jerks must be ascertained before choosing the appropriate therapy. Second, multiple drugs often must be used in combination to achieve functional improvement. Third, given the paucity of adequately controlled trials, the treating physician must rely on well-documented case series of patients with myoclonic syndromes who obtained benefit from a drug.
Frucht
S
Columbia-Presbyterian Medical Center, The Neurological Institute, 710 West 168th Street, New York, NY 10032, USA. frucht@movdis.cis.columbia.edu